Get the Stockscreener App
13.10
5.48%
0.68
Oric Pharmaceuticals Inc stock is traded at $13.10, with a volume of 1.46M.
It is up +5.48% in the last 24 hours and up +25.24% over the past month.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
See More
Previous Close:
$12.42
Open:
$12.58
24h Volume:
1.46M
Relative Volume:
1.09
Market Cap:
$1.27B
Revenue:
-
Net Income/Loss:
$-137.25M
P/E Ratio:
-6.9312
EPS:
-1.89
Net Cash Flow:
$-121.97M
1W Performance:
+2.50%
1M Performance:
+25.24%
6M Performance:
+152.41%
1Y Performance:
+55.21%
1-Day Range:
$12.47
$13.38
1-Week Range:
$11.71
$13.38
52-Week Range:
$3.8951
$14.93
Oric Pharmaceuticals Inc Stock (ORIC) Company Profile
Name
Oric Pharmaceuticals Inc
Sector
Industry
Phone
(650) 388-5600
Address
240 E. GRAND AVE., SOUTH SAN FRANCISCO, CA
Compare ORIC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ORIC
Oric Pharmaceuticals Inc
|
13.10 | 1.21B | 0 | -137.25M | -121.97M | -1.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.39 | 108.36B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
463.43 | 60.82B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
577.95 | 61.02B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
817.32 | 50.01B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
310.81 | 34.05B | 4.56B | -176.77M | 225.30M | -1.7177 |
Oric Pharmaceuticals Inc Stock (ORIC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-04-25 | Resumed | Guggenheim | Buy |
| Jul-08-25 | Initiated | Ladenburg Thalmann | Buy |
| Oct-31-24 | Initiated | Wells Fargo | Overweight |
| Sep-06-24 | Initiated | Stifel | Buy |
| Feb-23-24 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-22-23 | Initiated | Wedbush | Outperform |
| Mar-23-23 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Mar-21-23 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-16-23 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-18-22 | Resumed | Oppenheimer | Perform |
| Apr-04-22 | Upgrade | Citigroup | Neutral → Buy |
| Mar-25-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-22-22 | Downgrade | Citigroup | Buy → Neutral |
| Mar-22-22 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-22-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-06-21 | Upgrade | Citigroup | Neutral → Buy |
| Jan-25-21 | Downgrade | Citigroup | Buy → Neutral |
| Aug-13-20 | Initiated | Robert W. Baird | Outperform |
| Aug-06-20 | Upgrade | Citigroup | Neutral → Buy |
| Aug-03-20 | Initiated | H.C. Wainwright | Buy |
| May-19-20 | Initiated | Citigroup | Neutral |
| May-19-20 | Initiated | Guggenheim | Buy |
| May-19-20 | Initiated | JP Morgan | Overweight |
| May-19-20 | Initiated | Jefferies | Buy |
View All
Oric Pharmaceuticals Inc Stock (ORIC) Latest News
What technical models suggest about ORIC Pharmaceuticals Inc.’s comebackJuly 2025 Sector Moves & Weekly Market Pulse Updates - newser.com
Why ORIC Pharmaceuticals Inc. (4TZ) stock stays on top picksTrade Analysis Summary & Weekly Top Performers Watchlists - newser.com
Has ORIC Pharmaceuticals Inc. found a price floorJuly 2025 Setups & Technical Confirmation Trade Alerts - newser.com
Will ORIC Pharmaceuticals Inc. stock split again soonEarnings Risk Summary & Detailed Earnings Play Alerts - newser.com
Relative strength of ORIC Pharmaceuticals Inc. in sector analysisWeekly Gains Summary & AI Forecast for Swing Trade Picks - newser.com
Sentiment analysis tools applied to ORIC Pharmaceuticals Inc.July 2025 Retail & Risk Controlled Stock Pick Alerts - newser.com
How to read the order book for ORIC Pharmaceuticals Inc.July 2025 Review & Real-Time Chart Breakout Alerts - newser.com
Can you recover from losses in ORIC Pharmaceuticals Inc.2025 Breakouts & Breakdowns & Community Shared Stock Ideas - newser.com
Oric Pharmaceuticals, Inc. (ORIC) Investor Outlook: A Promising 47% Upside Potential Amid Innovative Cancer Therapies - DirectorsTalk Interviews
BDTX vs. ORIC: Which Oncology Focused Biotech Stock Is a Better Pick Now? - sharewise.com
TD Asset Management Inc Raises Position in Oric Pharmaceuticals, Inc. $ORIC - MarketBeat
Historical volatility pattern of ORIC Pharmaceuticals Inc. visualizedWeekly Profit Report & Verified Technical Trade Signals - newser.com
Candlestick signals on ORIC Pharmaceuticals Inc. stock todayEarnings Summary Report & Capital Efficient Trading Techniques - newser.com
Analyzing drawdowns of ORIC Pharmaceuticals Inc. with statistical tools2025 Winners & Losers & Weekly Consistent Profit Watchlists - newser.com
Published on: 2025-10-20 19:38:47 - newser.com
Oric Pharmaceuticals Inc Stock (ORIC) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):